Intranasal Oxytocin Investigated for Social Cognitive and Functional Deficits in Schizophrenia
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Abstract
A 12-week randomized, placebo-controlled trial investigated intranasal oxytocin (24 IU BID) for social cognition, psychotic symptoms, and social functioning in schizophrenia.